Back to results
US 2026/0097055 A1Published application
Cognition
OwnerSydney David CULLIS-HILLinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to acetyl glucosamine. In particular, the present invention relates to the use of acetyl glucosamine to improve cognition.
Claims16
-20. (canceled)
A method of treating Alzheimer's disease (AD) in a subject, comprising administering to the subject O-acetyl glucosamine or a salt or hydrate thereof, wherein the acetyl glucosamine has the following structure
- and wherein two or three of R1, R2, R3 and R4 are acetyl.
A method of treating preclinical AD or preventing AD or preventing preclinical AD in a subject, comprising administering to the subject O-acetyl glucosamine or a salt or hydrate thereof, wherein the O-acetyl glucosamine has the following structure
- and wherein two or three of R1, R2, R3 and R4 are acetyl.
A kit including:
- a container holding an O-acetyl glucosamine, a salt, hydrate, or pharmaceutical composition thereof;
- a label or package insert with instructions for use in treating AD in a subject, wherein the O-acetyl glucosamine has the following structure
- and wherein two or three of R1, R2, R3 and R4 are acetyl.
Dependencies are inferred from the claim text.